381 related articles for article (PubMed ID: 18650975)
1. Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches.
Kalofoutis C; Piperi C; Kalofoutis A; Harris F; Phoenix D; Singh J
Exp Clin Cardiol; 2007; 12(1):17-28. PubMed ID: 18650975
[TBL] [Abstract][Full Text] [Related]
2. Diabetes and cardiovascular risk markers.
Erdmann E
Curr Med Res Opin; 2005; 21 Suppl 1():S21-8. PubMed ID: 15811196
[TBL] [Abstract][Full Text] [Related]
3. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
[TBL] [Abstract][Full Text] [Related]
4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
5. Metabolic and additional vascular effects of thiazolidinediones.
Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
[TBL] [Abstract][Full Text] [Related]
6. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
7. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
Libby P; Plutzky J
Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056
[TBL] [Abstract][Full Text] [Related]
8. Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors.
Gerich JE
Clin Cornerstone; 2007; 8(3):53-68. PubMed ID: 18452842
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
Blaschke F; Caglayan E; Hsueh WA
Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
[TBL] [Abstract][Full Text] [Related]
10. Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment.
Yanai H; Adachi H; Hakoshima M; Katsuyama H
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408799
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Cavender MA; Lincoff AM
Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
[TBL] [Abstract][Full Text] [Related]
12. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
13. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.
Florkowski CM
Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Roberts AW; Thomas A; Rees A; Evans M
Curr Opin Lipidol; 2003 Dec; 14(6):567-73. PubMed ID: 14624133
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.
Krentz AJ
Diabetes Obes Metab; 2003 Nov; 5 Suppl 1():S19-27. PubMed ID: 14984018
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
Ríos-Vázquez R; Marzoa-Rivas R; Gil-Ortega I; Kaski JC
Am J Cardiovasc Drugs; 2006; 6(4):231-42. PubMed ID: 16913824
[TBL] [Abstract][Full Text] [Related]
17. Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence.
Sosale A; Saboo B; Sosale B
Diabetes Metab Syndr Obes; 2015; 8():189-96. PubMed ID: 25926748
[TBL] [Abstract][Full Text] [Related]
18. Diabetic dyslipidemia.
Kreisberg RA
Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
[TBL] [Abstract][Full Text] [Related]
19. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
Fonseca VA
Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
[TBL] [Abstract][Full Text] [Related]
20. Novel strategies for managing dyslipidemia: treatment beyond statins.
Ling H; Burns TL; Hilleman DE
Postgrad Med; 2012 Nov; 124(6):43-54. PubMed ID: 23322138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
